Array BioPharma

Array BioPharma
Traded as NASDAQ: ARRY
Russell 2000 Component
Headquarters Boulder, United States of America

Array BioPharma is a U.S.-based, clinical stage, publicly traded pharmaceutical company founded in Boulder, Colorado[1] (NASDAQ:ARRY)[2] that is included in the NASDAQ Biotechnology Index.[3]

The company has engaged in collaborations with Pfizer and Merck to study several cancer targeting drug combinations.[4][5] In July 2013 the company partnered with Loxo Oncology to develop cancer drugs[6], in November 2015 the company partnered with Pierre Fabre[7] and the company also partnered with Ono Pharmaceutical in March 2016 to test the combination of binimetinib and encorafenib while retaining commercialization rights in the U.S. and other markets.[8][9]

In 2017 it spun out one of its programs into a subsidiary called Yarra; the asset was a molecule called ARRY-797 that was in a Phase II trial for cardiomyopathy.[1]

In March 2018 Array sued AstraZeneca for breach of contract, saying that AZ owed it a 12% royalty on a portion of the $1.6 billion upfront payment that Merck had paid to AZ in a deal for selumetinib, which Array said it had licensed to AZ in 2003.[10]

In June 2018, the combination of Braftovi (encorafenib) and Mektovi (binimetinib) were approved by the FDA for the treatment of people with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma.[11]

References

  1. 1 2 Castle, Shay (December 26, 2017). "Boulder's Array BioPharma spins out subsidiary to develop rare-disease drugs". The Denver Post.
  2. ↑ "Array BioPharma Inc. (ARRY)". NASDAQ.com. NASDAQ OMX Group. Retrieved 3 January 2016.
  3. ↑ "^NBI Components NASDAQ Biotechnology Stock - Yahoo! Finance". finance.yahoo.com. Yahoo Finance. Retrieved 5 June 2017.
  4. ↑ Al Idrus, Amirah (December 19, 2017). "Array Biopharma ties up with Pfizer on cancer-fighting combos". =FierceBiotech.
  5. ↑ Hughes, Emily (6 June 2016). "Merck, Pierre Fabre and Array BioPharma collaborate for cancer drug clinical trial". EPM Magazine.
  6. ↑ "Array, Loxo Ink $434M+ Deal for Small Molecule Cancer Drug Development". Genetic Engineering News. July 10, 2013.
  7. ↑ Lawrence, Stacy (September 26, 2016). "Array up by more than half on PhIII melanoma combo data". FierceBiotech.
  8. ↑ Taylor, Phil (May 31, 2017). "Array adds Ono as Japanese partner for MEK/BRAF combo". FierceBiotechm.
  9. ↑ Vinluan, Frank (June 1, 2017). "Array Lands $31M in Licensing Deal with Japan's Ono Pharma". Xconomy.
  10. ↑ Vogt, RJ (March 19, 2018). "AstraZeneca Owes $192M For Cancer Drug Rights, Rival Says". Law360.
  11. ↑ "Press release: FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations". FDA. June 27, 2018.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.